MabGenesis
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biotech startup using proprietary antibody libraries to develop species-specific therapeutics for human oncology and veterinary medicine.
OncologyImmunology
Technology Platform
Proprietary MOURA antibody libraries (species-specific for human, canine, feline) combined with the IMPACT high-efficiency monoclonal antibody isolation technology.
Opportunities
The rapidly growing companion animal therapeutics market, projected to reach $6B by 2032, and the demand for safer, fully species-specific antibodies in both human and veterinary medicine.
Risk Factors
As an early-stage platform company, it faces risks of failing to secure validation partnerships, competition from established antibody discovery platforms, and the significant cost and complexity of dual human/veterinary development.
Competitive Landscape
Competes with large antibody discovery CROs (e.g., Abzena, Ligand's OmniAb) and animal health companies in veterinary biologics; differentiation is its claim of superior library quality and focus on 100% species-specific antibodies for pets.